In the tapestry of entrepreneurship, Mark Hollard stands as a luminary, a serial entrepreneur in the consumer health space for over two decades. His journey, etched with successful exits from ventures aiming at affordable healthcare access, took a transformative turn with the inception of Choose Your Horizon Inc.

The genesis of Choose Your Horizon is rooted in a mission—to make affordable access to psychedelic therapy a reality across the United States. Founded and led by two seasoned consumer health entrepreneurs, the company is navigating uncharted waters in the burgeoning telemedicine landscape, offering at-home Ketamine Therapy as a beacon of hope for those who've exhausted conventional treatments.

Mark Hollard's inspiration sprang from witnessing the struggles of those grappling with mental illness, a silent battle where conventional therapies often fall short. Choose Your Horizon emerges as a lifeline, a visionary telemedicine platform providing an alternative for the 90 million people combating anxiety, depression, and PTSD.

What sets Choose Your Horizon apart is not just its innovative approach but a commitment to a responsible, patient-centric paradigm. Their clinician-based, safe, and legal process administers low-dose Ketamine treatments, ensuring a <1% reported adverse reaction rate. It's about more than just innovation; it's about safety, efficacy, and a dedication to standardizing psychedelic therapy.

The journey, however, wasn't without its challenges. Mental health disorders were on the rise, but traditional treatments lacked efficacy for a significant portion of patients. Enter psychedelic therapy, a rapid-acting alternative with lasting effects. Choose Your Horizon became a torchbearer, driving change and providing a pathway to transformation.

Fueling this journey is a company culture where people come first. Patient safety and efficacy take precedence, steering Choose Your Horizon's impressive growth. Operating in 13 states and reaching 47% of the U.S. population, the company aims to expand to all 50 states by 2024.

The milestones achieved are testament to the impact—over $1.5 million in packages sold in 2023, 2,200 treatment packages delivered, and more than 6,000 transformative Ketamine-Assisted Therapy sessions across 15 states. The numbers reveal a story of hope, with 98% of clients witnessing symptom improvement and <1% experiencing adverse effects.

As a thought leader, Mark envisions the future trends converging towards psychedelic therapy. With the Psychedelics Market set to reach $11.82 billion by 2029, and telemedicine showing a robust 10.6% CAGR, Choose Your Horizon is at the intersection, reshaping the mental health landscape.

Embracing equity crowdfunding, Mark sees it as a tool to democratize access to growth companies, aligning with Choose Your Horizon's mission to democratize access to affordable and responsible psychedelic therapy.

For aspiring founders, Mark's advice is simple—persevere and stay focused on the mission. Rome wasn't built in a day, but Choose Your Horizon is crafting a new horizon for mental health, one transformative journey at a time.